Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 2025-08-28
SUPPLEMENT ANNOUNCEMENT CONNECTED TRANSACTION - TECHNOLOGY DEVELOPMENT COLLABORATION WITH SUZHOU ALPHAMAB 2025-08-18
POSITIVE PROFIT ALERT 2025-08-13
DATE OF BOARD MEETING 2025-08-12
CONNECTED TRANSACTION ANNOUNCEMENT – TECHNOLOGY DEVELOPMENT COLLABORATION WITH SUZHOU ALPHAMAB 2025-08-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 2025-08-05
VOLUNTARY ANNOUNCEMENT – IND APPLICATION FOR JSKN022 WAS OFFICIALLY ACCEPTED BY THE CDE 2025-08-03
VOLUNTARY ANNOUNCEMENT – JSKN003 RECEIVED THE U.S. FDA APPROVAL TO INITIATE A PHASE II CLINICAL STUDY IN THE TREATMENT OF PROC NOT RESTRICTED BY HER2 EXPRESSION 2025-07-31
VOLUNTARY ANNOUNCEMENT – JSKN003 FOR THE TREATMENT OF GC/GEJ WAS GRANTED ODD BY THE U.S. FDA 2025-07-29
Next Day Disclosure Return 2025-07-17